glp 1 fast food options GLP-1s are saving people from obesity. Are they killing restaurants? Fast food chains are rolling

Mini Rev

Wegovy cardiovascular risk reduction In March 2024, the FDA approved Wegovy for reducing the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with established cardiovascular disease and overweight or obesity

Beyond their role in weight reduction, which itself can lessen mechanical friction and inflammation in intertriginous areas, GLP-1s improve insulin sensitivity, cardiometabolic risk factors, and may reduce systemic inflammationall of which can be more prevalent in HS patients

I am enjoying the weight loss I have experienced so far and I am looking for to meeting my goal weight very soon

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis

In some cases, this might lead to elevated liver enzymes or, less commonly, issues like pancreatitis